MedTrace Logo

Modafinil Augmentation in Chronic Schizophrenia and Schizoaffective Disorder

NCT00838227 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-10-14

No results posted yet for this study

Summary

This is an open label 8-week trial of modafinil up to 400 mg daily added to a stable antipsychotic regimen to evaluate the effect modafinil on cognition, sedation, and weight in patients with chronic schizophrenia. We hypothesize that modafinil, a wake-promoting agent, will lead to improved cognition, increased wakefulness, and decreased weight in patients with schizophrenia who are on stable antipsychotic regimens

Conditions

Interventions

DRUG

modafinil

Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen

Sponsors & Collaborators

  • Manhattan Psychiatric Center

    lead OTHER

Principal Investigators

  • Jean-Pierre Lindenmayer, MD · Manhattan Psychiatric Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2012-01-31
Completion
2012-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00838227 on ClinicalTrials.gov